WAY-100635 maleate is a potent, selective 5-HT1A receptor antagonist with an IC50 value of 0.91 nM, a Ki value of 0.39 nM, and a pIC50 of 8.87, which is more than 100-fold more selective than for use at the other 5-HT receptor subtypes and major neurotransmitter receptors. In addition, WAY-100635 maleate is a potent dopamine D4 receptor agonist.
Way-181187 (SAX-187) is an effective selective 5-HT6 receptor agonist with Ki of 2.2 nM and EC50 of 6.6 nM. WAY181187 mediates 5-HT6 receptor-dependent signaling pathways, such as cAMP, Fyn and ERK1/2 kinases, as specific agonists.
Way-181187 (SAX-187) is an effective selective 5-HT6 receptor agonist with Ki of 2.2 nM and EC50 of 6.6 nM. WAY181187 mediates 5-HT6 receptor-dependent signaling pathways, such as cAMP, Fyn and ERK1/2 kinases, as specific agonists.
Way-213613 is a potent, selective, non-substrate reuptake inhibitor of GLT-1/EAAT2 with an IC50 of 85 nM against EAAT2. The selectivity of WAY-213613 hydrochloride to EAAT1 and EAAT3 was 59 and 44 times higher (IC50 was 5 and 3.8 μM, respectively). Way-213613 has no activity on ionic and metabolic glutamate receptors.
Way-213613 is a potent, selective, non-substrate reuptake inhibitor of GLT-1/EAAT2 with an IC50 of 85 nM against EAAT2. The selectivity of WAY-213613 hydrochloride to EAAT1 and EAAT3 was 59 and 44 times higher (IC50 was 5 and 3.8 μM, respectively). Way-213613 has no activity on ionic and metabolic glutamate receptors.
WAY-262611 is a Wnt pathway agonist acting via inhibition of Dkk1 with no GSK-3β inhibition and the TCF-Luciferase EC50=0.63µM.
WAY-262611 is a Wnt pathway agonist acting via inhibition of Dkk1 with no GSK-3β inhibition and the TCF-Luciferase EC50=0.63µM.
WAY-262611 is a Wnt pathway agonist acting via inhibition of Dkk1 with no GSK-3β inhibition and the TCF-Luciferase EC50=0.63µM.
WAY-262611 is a Wnt pathway agonist acting via inhibition of Dkk1 with no GSK-3β inhibition and the TCF-Luciferase EC50=0.63µM.